Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

3.80
+0.02000.53%
Post-market: 3.820.0175+0.46%19:55 EDT
Volume:1.20M
Turnover:4.54M
Market Cap:183.54M
PE:-1.49
High:3.94
Open:3.78
Low:3.70
Close:3.78
52wk High:33.98
52wk Low:1.15
Shares:48.30M
Float Shares:43.48M
Volume Ratio:0.55
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5569
EPS(LYR):-0.5254
ROE:-88.95%
ROA:-29.68%
PB:2.09
PE(LYR):-7.23

Loading ...

Company Profile

Company Name:
Cassava Sciences Inc
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
30
Office Location:
6801 N. Capital of Texas Highway,Suite 300,Building 1,Austin,Texas,United States
Zip Code:
78731
Fax:
- -
Introduction:
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Directors

Name
Position
Claude Nicaise
Chairman of the Board and Director
Richard J. Barry
President, Chief Executive Officer and Director
Dawn Carter Bir
Director
Michael J. O'donnell
Director
Patrick J. Scannon
Director
Pierre Gravier
Director
Robert Anderson
Director
Robert Z. Gussin
Director

Shareholders

Name
Position
Richard J. Barry
President, Chief Executive Officer and Director
R. Christopher Cook
Chief Operating Officer and Chief Legal Officer
Eric J. Schoen
Chief Financial Officer
Freda Nassif
Chief Business Officer